Folgen
Carlos G. Santos-Gallego
Carlos G. Santos-Gallego
Cardiology Department, The Mount Sinai Hospital. Cardiovascular Institute, Icahn School of Medicine
Bestätigte E-Mail-Adresse bei mssm.edu
Titel
Zitiert von
Zitiert von
Jahr
Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics
CG Santos-Gallego, JA Requena-Ibanez, R San Antonio, K Ishikawa, ...
Journal of the American College of Cardiology 73 (15), 1931-1944, 2019
5132019
Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction
CG Santos-Gallego, AP Vargas-Delgado, JA Requena-Ibanez, ...
Journal of the American College of Cardiology 77 (3), 243-255, 2021
3512021
Pathophysiology of acute coronary syndrome
CG Santos-Gallego, B Picatoste, JJ Badimón
Current atherosclerosis reports 16, 1-9, 2014
3132014
Sphingosine-1-phosphate receptor agonist fingolimod increases myocardial salvage and decreases adverse postinfarction left ventricular remodeling in a porcine model of ischemia …
CG Santos-Gallego, TP Vahl, G Goliasch, B Picatoste, T Arias, K Ishikawa, ...
Circulation 133 (10), 954-966, 2016
1672016
Mechanistic insights of empagliflozin in nondiabetic patients with HFrEF: from the EMPA-TROPISM study
JA Requena-Ibáñez, CG Santos-Gallego, A Rodriguez-Cordero, ...
Heart Failure 9 (8), 578-589, 2021
1562021
Rapid Change in Plaque Size, Composition, and Molecular Footprint After Recombinant Apolipoprotein A-IMilano (ETC-216) Administration: Magnetic Resonance …
B Ibanez, G Vilahur, G Cimmino, WS Speidl, A Pinero, BG Choi, MU Zafar, ...
Journal of the American College of Cardiology 51 (11), 1104-1109, 2008
1542008
Empagliflozin ameliorates diastolic dysfunction and left ventricular fibrosis/stiffness in nondiabetic heart failure: a multimodality study
CG Santos-Gallego, JA Requena-Ibanez, R San Antonio, ...
Cardiovascular Imaging 14 (2), 393-407, 2021
1382021
SUMO-1 gene transfer improves cardiac function in a large-animal model of heart failure
L Tilemann, A Lee, K Ishikawa, J Aguero, K Rapti, C Santos-Gallego, ...
Science translational medicine 5 (211), 211ra159-211ra159, 2013
1142013
Recombinant HDLMilano exerts greater anti-inflammatory and plaque stabilizing properties than HDLwild-type
B Ibanez, C Giannarelli, G Cimmino, CG Santos-Gallego, M Alique, ...
Atherosclerosis 220 (1), 72-77, 2012
1132012
The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments
A Garcia-Ropero, JJ Badimon, CG Santos-Gallego
Expert Opinion on Drug Metabolism & Toxicology 14 (12), 1287-1302, 2018
1102018
Beginning to understand high-density lipoproteins
CG Santos-Gallego, JJ Badimon, RS Rosenson
Endocrinology and Metabolism Clinics 43 (4), 913-947, 2014
1102014
Characterization of right ventricular remodeling and failure in a chronic pulmonary hypertension model
J Aguero, K Ishikawa, L Hadri, C Santos-Gallego, K Fish, N Hammoudi, ...
American Journal of Physiology-Heart and Circulatory Physiology 307 (8 …, 2014
992014
Pioglitazone induces vascular smooth muscle cell apoptosis through a peroxisome proliferator-activated receptor-γ, transforming growth factor-β1, and a Smad2-dependent mechanism
S Redondo, E Ruiz, CG Santos-Gallego, E Padilla, T Tejerina
Diabetes 54 (3), 811-817, 2005
992005
Cardiac I-1c overexpression with reengineered AAV improves cardiac function in swine ischemic heart failure
K Ishikawa, KM Fish, L Tilemann, K Rapti, J Aguero, CG Santos-Gallego, ...
Molecular therapy 22 (12), 2038-2045, 2014
852014
Acetylsalicylic acid inhibits cell proliferation by involving transforming growth factor-β
S Redondo, CG Santos-Gallego, P Ganado, M García, L Rico, M Del Rio, ...
Circulation 107 (4), 626-629, 2003
822003
HDL-cholesterol: Is it really good?: Differences between apoA-I and HDL
CG Santos-Gallego, B Ibanez, JJ Badimon
Biochemical pharmacology 76 (4), 443-452, 2008
742008
Intratracheal gene delivery of SERCA2a ameliorates chronic post-capillary pulmonary hypertension: a large animal model
J Aguero, K Ishikawa, L Hadri, CG Santos-Gallego, KM Fish, ...
Journal of the American College of Cardiology 67 (17), 2032-2046, 2016
672016
Role of HDL in those with diabetes
CG Santos-Gallego, RS Rosenson
Current cardiology reports 16, 1-14, 2014
672014
Metabolism of the failing heart and the impact of SGLT2 inhibitors
A Garcia-Ropero, CG Santos-Gallego, MU Zafar, JJ Badimon
Expert opinion on drug metabolism & toxicology 15 (4), 275-285, 2019
652019
HDL: Quality or quantity?
CG Santos-Gallego
Atherosclerosis 243 (1), 121-123, 2015
632015
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20